Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors

N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide (NHPPC) is a new potential of type 5 phosphodiesterase (PDE5) inhibitors, synthesized from the avanafil analogue for the treatment of erectile dysfunction. The targets of this article were...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Haijun, Hu, Xiaoxiao, Shi, Xiaoli, Wang, Chuan, Wang, Longyuan, Wang, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Molecular & Cellular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567057/
https://www.ncbi.nlm.nih.gov/pubmed/31231578
http://dx.doi.org/10.1080/19768354.2019.1614091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567057/
https://www.ncbi.nlm.nih.gov/pubmed/31231578
http://dx.doi.org/10.1080/19768354.2019.1614091

Ejemplares similares